JP2019536770A - 予め会合され、保護され、化学的に安定した、官能基選択的リンカー - Google Patents

予め会合され、保護され、化学的に安定した、官能基選択的リンカー Download PDF

Info

Publication number
JP2019536770A
JP2019536770A JP2019524074A JP2019524074A JP2019536770A JP 2019536770 A JP2019536770 A JP 2019536770A JP 2019524074 A JP2019524074 A JP 2019524074A JP 2019524074 A JP2019524074 A JP 2019524074A JP 2019536770 A JP2019536770 A JP 2019536770A
Authority
JP
Japan
Prior art keywords
alkyl
amino
molecule
salt
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019524074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536770A5 (enExample
Inventor
パトリック・ウォルシュ
デイビッド・スミス
ゴーラブ・サイニ
ジェイ・エイチ・パク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HealthTell Inc
Original Assignee
HealthTell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HealthTell Inc filed Critical HealthTell Inc
Publication of JP2019536770A publication Critical patent/JP2019536770A/ja
Publication of JP2019536770A5 publication Critical patent/JP2019536770A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C07F7/087—Compounds of unknown structure containing a Si-O-Si sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
JP2019524074A 2016-11-09 2017-11-08 予め会合され、保護され、化学的に安定した、官能基選択的リンカー Withdrawn JP2019536770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419861P 2016-11-09 2016-11-09
US62/419,861 2016-11-09
PCT/US2017/060721 WO2018089554A1 (en) 2016-11-09 2017-11-08 Pre-assembled, protected, chemically stable, chemoselective linkers

Publications (2)

Publication Number Publication Date
JP2019536770A true JP2019536770A (ja) 2019-12-19
JP2019536770A5 JP2019536770A5 (enExample) 2020-12-17

Family

ID=62109408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524074A Withdrawn JP2019536770A (ja) 2016-11-09 2017-11-08 予め会合され、保護され、化学的に安定した、官能基選択的リンカー

Country Status (8)

Country Link
US (1) US12037311B2 (enExample)
EP (1) EP3538536A4 (enExample)
JP (1) JP2019536770A (enExample)
KR (1) KR20190082871A (enExample)
CN (2) CN116514861A (enExample)
AU (1) AU2017359448A1 (enExample)
CA (1) CA3043373A1 (enExample)
WO (1) WO2018089554A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
WO2017223117A1 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
JP2019536860A (ja) 2016-11-09 2019-12-19 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 調整可能なアミン比重を有するコーティング
CN116514861A (zh) 2016-11-09 2023-08-01 库博科学公司 预组装的、受保护的、化学稳定的化学选择性接头
CN110168370A (zh) 2016-11-11 2019-08-23 健康之语公司 用于鉴定候选生物标志物的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
GB0001513D0 (en) 2000-01-25 2000-03-15 Univ Cranfield Rational design of mips using computational approach
JP5078212B2 (ja) * 2000-06-02 2012-11-21 ブラッコ・スイス・ソシエテ・アノニム 内皮細胞を標的とするための化合物、それを含む組成物およびその使用方法
US20030219816A1 (en) 2001-07-02 2003-11-27 Keith Solomon Composite microarray slides
CN1125488C (zh) 2000-08-25 2003-10-22 中国科学院化学研究所 一种半导体封装用的液体环氧组合物及其用途
JP4398644B2 (ja) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
US20030003223A1 (en) 2001-04-07 2003-01-02 The Regents Of The University Of California Methods and compositions for binding histidine-containing proteins to substrates
GB0121602D0 (en) 2001-09-06 2001-10-24 Randox Lab Ltd Molecular array
JP2005529335A (ja) 2002-06-10 2005-09-29 フィネクサス， インク． 開放チャンネルを使って生体分子を固体相として抽出するシステムと方法
US20060013971A1 (en) 2002-10-25 2006-01-19 Tienteh Chen Porous inkjet recording material
WO2004053068A2 (en) 2002-12-05 2004-06-24 Incyte Corporation Protein modification and maintenance molecules
KR100529600B1 (ko) 2003-01-23 2005-11-22 정만길 디옥소아테미시닌 유사체, 그의 제조방법 및 그를포함하는 항암제
JP4006523B2 (ja) 2003-04-10 2007-11-14 独立行政法人産業技術総合研究所 タンパク質アレイ及びその作製方法
WO2005050224A2 (en) 2003-11-13 2005-06-02 Epitome Biosystems Inc. Small molecule and peptide arrays and uses thereof
EP1689863B1 (en) 2003-11-15 2014-05-28 Polyphor Ltd. Template fixed beta-hairpin loop mimetics and their use in phage display
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
ES2484796T3 (es) * 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US7507480B2 (en) 2005-05-31 2009-03-24 Brookhaven Science Associates, Llc Corrosion-resistant metal surfaces
KR100671659B1 (ko) * 2005-12-21 2007-01-19 삼성에스디아이 주식회사 데이터 구동부 및 이를 이용한 유기 발광 표시장치와 그의구동방법
US7923054B2 (en) 2006-04-19 2011-04-12 Gore Enterprise Holdings, Inc. Functional porous substrates for attaching biomolecules
WO2007144685A1 (en) 2006-06-13 2007-12-21 Commissariat A L'energie Atomique Cd4 mimic peptides and their uses
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
JP2008028123A (ja) 2006-07-20 2008-02-07 Sanyo Electric Co Ltd 半導体集積回路装置の製造方法
WO2008064336A2 (en) 2006-11-22 2008-05-29 Inivitrogen Corporation Autoimmune disease biomarkers
US20090176664A1 (en) 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
WO2008156867A1 (en) 2007-06-21 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for the diagnosis of autoimmune disease
JP2011001344A (ja) 2009-04-30 2011-01-06 L'oreal Sa アミノトリアルコキシシランまたはアミノトリアルケニルオキシシラン組成物を用いたヒトケラチン繊維の明色化および／または着色ならびに装置
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
CA2768149A1 (en) 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
WO2011041586A1 (en) 2009-09-30 2011-04-07 Virogenomics, Inc. Electromagnetic detection of analytes
US8698320B2 (en) 2009-12-07 2014-04-15 Henkel IP & Holding GmbH Curable resin compositions useful as underfill sealants for use with low-k dielectric-containing semiconductor devices
US20130071860A1 (en) 2010-02-24 2013-03-21 Matthew B. Hale Methods for autoimmune disease diagnosis, prognosis, and treatment`
US20120237555A1 (en) 2011-03-16 2012-09-20 David Williams Surface coating for biomolecule immobilisation and minimisation of non-specific binding on surfaces for biomedical diagnostics
US9346892B2 (en) 2011-03-18 2016-05-24 Roche Nimble Gen, Inc. Methods for synthesis of an oligopeptide microarray
WO2013077982A1 (en) 2011-11-22 2013-05-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf High throughput selection of specific cell binding and lytic polypeptides
WO2013119845A1 (en) 2012-02-07 2013-08-15 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
US20130310265A1 (en) 2012-03-21 2013-11-21 North Carolina State University Methods of preparing cyclic peptides and uses thereof
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
CN104781668B (zh) 2012-08-29 2018-07-24 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 免疫特征分析：通向早期诊断和健康监测的途径
CN107817348A (zh) * 2012-09-05 2018-03-20 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
WO2014062981A1 (en) 2012-10-17 2014-04-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University In situ chemical patterning
US9970932B2 (en) * 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
US20170212101A1 (en) 2014-07-18 2017-07-27 Cdi Laboratories, Inc. Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
JP6824903B2 (ja) 2015-04-23 2021-02-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ペプチド環化およびプロテアーゼ処理のための方法および組成物
US10094825B2 (en) 2015-07-30 2018-10-09 The Florida International University Board Of Trustees Predictive biomarkers for detection of organ damage in autoimmune illnesses and other diseases
JP2019520421A (ja) 2016-04-01 2019-07-18 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 治療抗体の特徴付けのためのアレイに基づくペプチドライブラリー
CN116514861A (zh) 2016-11-09 2023-08-01 库博科学公司 预组装的、受保护的、化学稳定的化学选择性接头
JP2019536860A (ja) 2016-11-09 2019-12-19 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 調整可能なアミン比重を有するコーティング
US20200116715A1 (en) 2017-06-19 2020-04-16 Healthtell Inc. Immunosignatures for differential diagnosis
EP3749676A4 (en) 2018-02-09 2021-12-22 Healthtell Inc. NETWORK BASED CYCLIC PEPTIDE BANKS
US20220010301A1 (en) 2018-11-14 2022-01-13 Cowper Sciences Inc. Methods of selecting functional interface mimics, and compositions thereof

Also Published As

Publication number Publication date
AU2017359448A1 (en) 2019-05-30
CN110072870A (zh) 2019-07-30
WO2018089554A1 (en) 2018-05-17
EP3538536A1 (en) 2019-09-18
EP3538536A4 (en) 2020-05-13
CA3043373A1 (en) 2018-05-17
US20190359566A1 (en) 2019-11-28
KR20190082871A (ko) 2019-07-10
CN116514861A (zh) 2023-08-01
US12037311B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
US20220290005A1 (en) Coatings with tunable amine density
US12037311B2 (en) Pre-assembled, protected, chemically stable, chemoselective linkers
Seong et al. Current status of protein chip development in terms of fabrication and application
Jason‐Moller et al. Overview of Biacore systems and their applications
US20240094207A1 (en) Serological biomarkers for early diagnosis of lung cancer
Simões et al. Direct immobilization of engineered nanobodies on gold sensors
WO2018031247A1 (en) Apparatuses and methods for detecting molecules and binding energy
Meng et al. The role of peptide microarrays in biomedical research
US10191049B2 (en) Screening methods and uses thereof
Talucci et al. Peptide microarrays for studying autoantibodies in neurological disease
US20230096980A1 (en) Methods and systems for mask alignment in manufacturing process of arrays
US20260018241A1 (en) Methods of isolating anti-ligands
US20230265481A1 (en) Method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
KR20100127948A (ko) Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용
EP3274724A1 (en) A method for measuring the protease activity of factor d of the alternative complement pathway
EP3602067B1 (en) Methods and kits for determining binding sites
Yamamoto et al. Microarray technologies for intracellular kinome analysis
Liu et al. Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes
Bertucci et al. Optical biosensors and applications to drug discovery and development in cancer research
AU2004264178A1 (en) Method for detecting low levels of a fusion protein
Li et al. Estimation of interaction between oriented immobilized green fluorescent protein and its antibody by high performance affinity chromatography and molecular docking
HK40117257A (en) Methods of isolating anti-ligands
Schofield et al. The recombinant protein array: use in target identification and validation
Santos et al. A Label-Free Nanobody-Conjugated Interferometric Protein Sensor
Dyson et al. Multiplexing affinity maturation to generate antibodies of high affinity and specificity to multiple SH2 domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20201217